Showing posts with label intact rotator cuff. Show all posts
Showing posts with label intact rotator cuff. Show all posts

Tuesday, June 16, 2026

aTSA vs RSA for cuff intact arthritis: what is the evidence that informs the choice for each patient?


Both anatomic total shoulder arthroplasty (aTSA) and reverse shoulder arthroplasty (RSA) are considerations for patients with cuff-intact glenohumeral osteoarthritis. Currently many, if not most shoulder surgeons are trending toward RSA. In fact many surgeons have little working experience in performing aTSA. For example, per the Australian registry, the share of primary total shoulder replacements that is anatomic has collapsed from roughly 57% in 2008 to about 4% by 2024, while stemmed reverse has risen to nearly 90% (see figure below) [1]. In some circles the pro RSA argument is based on the contentions that (1) the RSA is easier to perform by less experienced-as well as experienced-surgeons and (2) the RSA as a lower rate of revision.

A look at the published evidence may inform the choice for patients and surgeons:

1. Patient-reported outcomes

With commonly used scores, the two types of arthroplasty seem similar for cuff-intact arthritis. A 2026 meta-analysis of 1,716 patients aged ≥70 with a competent cuff found no significant differences in ASES, Constant, or SST scores [2]. A meta-analysis of 14 studies (4,819 cases) found similar ASES, Constant, SST, SSV, and VAS pain scores [3], as did an earlier systematic review [4] and a propensity score–matched JBJS analysis [5]. 

However, in the UK National Joint Registry, roughly a quarter of 21,918 RSA patients had an “unsatisfactory” Oxford Shoulder Score (<29) [6]. Single-center series using patient-acceptable-symptom-state (PASS) thresholds put the figure higher — 25–40% of RSA patients failed to reach PASS for ASES or SANE at two years [7], and 34–35% still failed at minimum five years [8], with pain the primary factor in these adverse outcomes. 

With the Shoulder Arthroplasty Smart score, aTSA achieved higher absolute postoperative scores even though the improvement from baseline was similar [9]. Among patients who reached a “new normal” (defined as a SANE score  ≥95), aTSA significantly outperformed RSA on higher-demand tasks, motion, and return to sport and work [10]. 

2. Motion 

Across the comparative meta-analyses, aTSA delivered better external and internal rotation, with differences that exceed the MCID and reached 10–11° of external rotation in pooled estimates [2,3,4] as well as  better overall motion in matched cohorts [5]. Rotation enables the patient to perform basic activities of daily living: dressing, toileting, perineal care, and reaching behind the back.

3. Complications

In pooled comparative data, RSA carried a lower overall complication rate than aTSA in the cuff-intact population [2,3]. But the complications the two implants produced differed in kind. Historically, primary stemmed anatomic shoulders done for osteoarthritis using legacy techniques and implants have been revised chiefly for glenoid component loosening (29.1%), rotator cuff insufficiency (27.6%), and instability/dislocation (23.1%), with loosening being predominant [1]. Stemmed reverse shoulders have been revised chiefly for instability/dislocation, infection, loosening, and fracture [1]. 

4. Revision 

At ten years, cumulative percent revision (all diagnoses, modern prostheses) was 5.5% for stemmed reverse, 5.2% for stemless aTSA, and 7.9% for stemmed aTSA (Figure 2 below) [1]. 

It is worthwhile noting that the 7.9% ten-year revision rate for stemmed aTSA includes decades of older, non-crosslinked polyethylene. When the glenoid is crosslinked, aTSA durability improves markedly: in a dedicated AOANJRR study of 10,102 stemmed aTSAs done for osteoarthritis, non-crosslinked polyethylene had more than double the revision risk of crosslinked polyethylene after 18 months (HR 2.3; 95% CI 1.6–3.1), with 12-year cumulative revision of 9% versus 5% [22]. Considering only crosslinked anatomic glenoids, the revision rate for stemmed aTSAs (5%) was comparable to stemmed RSA (5.5%) and stemless aTSA (5.2%). 

Vitamin E–stabilized polyethylene is a type of crosslinked polyethylene, and registries tend to pool the two.  Vitamin E reduces wear and osteolytic particle debris on the bench [23], but no study has yet demonstrated a vitamin-E–versus–plain-crosslinked revision difference in shoulder arthroplasty.

The revision rates for stemless aTSA match those for the RSA; the reasons for this are not clear - perhaps more experienced surgeons, greater ability to achieve the desired humeral component position,  a higher rate of use of modern glenoid components, and/or preferential selection of healthier shoulders with better quality bone. 

Comparative meta-analyses report RSA revision rates about four-fold lower than aTSA in the cuff-intact analysis, OR 0.43; 95% CI 0.29–0.65; p<0.001) [3], although an earlier meta-analysis found no mid-term difference (OR 0.33; p=0.16) [4]. A 2026 propensity-matched study showed a lower early revision rate for aTSAs, but at midterm followup the revision rate increased [12].

However, it is critical to recognize that revision is a poor proxy for clinical failure in RSA. A National Joint Registry analysis concluded that low RSA revision rates may not signify implant success. Instead, patients with poor outcomes and their surgeons may be reluctant to undertake complex RSA revisions which have unpredictable results.[6]. The point is apparent for the most common mode of RSA failure — a painful, poorly functioning but radiographically satisfactory RSA. Such an outcome is experienced by about a quarter of RSA patients [6,7,8], yet RSAs are rarely revised for this indication. A failure that is not revised never appears in the revision rate.

[Complication frequencies were drawn from indexed systematic reviews [26–29] (e.g., PJI 2.4%, acromial/scapular fracture 2.5%, primary-RSA instability 2.5%); the revisability column reflects their reported management — acromial fractures are predominantly treated non-operatively, instability usually presents within 90 days and is treated by component revision, and infection is nearly always surgical. The registry anchor for pain/PROM failure is O’Malley [6].]

The different failure types are not equally salvageable. If an anatomic shoulder fails, it can usually be converted to a RSA with outcomes that approach those of primary RSA.  Primary stemmed anatomic shoulders done for osteoarthritis are revised to a reverse in 89% of cases, keeping the original humeral stem 58% of the time [1]; 93.8% of failed stemless aTSAs are converted to RSAs. On the other hand, revision of a failed reverse to another reverse often fails to yield the desired improvement in comfort and function.

5. Durability

Durability matters most for the patient with decades of active use ahead. At minimum ten-year follow-up, aTSAs sustain their functional gains for primary osteoarthritis [13], the large concurrent aTSA experience supports this option in the high-demand patient who wishes to avoid a RSA [14]. The Australian registry shows modern stemless anatomic matching reverse on revision out to ten years, and crosslinked stemmed-anatomic glenoids more than halve the revision risk of older non-crosslinked ones [1,22].

6. Return to sport 

Return-to-sport rates are high after both implants and highest after aTSA in pooled data [15]. A recent large weightlifting series reported high self-rated comfort, yet its endpoint is a single ordinal “difficulty” item — capturing neither the amount of load nor performance. [16]. When actual one-repetition-max recovery is measured, returners perform below their presymptomatic level, with the largest decrement in bench press [17]. 

7. Surgeon capability. It is often said that a good aTSA outperforms a good RSA, which outperforms a bad aTSA, which outperforms a bad RSA [18].  Some say it is technically easier to do a good RSA than an aTSA (not my view). However it is for sure that as aTSA volume falls, fewer surgeons will be able to reliably provide a good anatomic to their patients with cuff intact arthritis. While some hold that navigation, patient-specific instrumentation, and robotics may improve component positioning; none has been shown to improve patient-reported outcomes or reduce complications for any type of arthroplasty [19,20,21]. It appears that the surgeon is sill the method.

So, in rough summary

Bottom line: 

The patient and the surgeon considering arthroplasty for cuff intact shoulder arthritis should discuss the available evidence on aTSA and RSA.

An aTSA - when performed by a surgeon who can deliver a reliable aTSA -  may be attractive when function and salvageability matter most —  particularly in the more active patient with a reconstructable glenoid.

A RSA may be more attractive in the less active patient, or one whose glenoid morphology or bone quality makes a durable aTSA less certain or when the shoulder surgeon is not comfortable performing an anatomic shoulder arthroplasty.

Two cautions bear on the consideration: the revision rate understates RSA failure, because its most common failure — a painful but intact shoulder — is rarely revised [6]; and roughly a quarter of RSA patients do not reach a satisfactory outcome at all [6,7,8]. 


A choice


Pileated Woodpeckers
Seattle

Follow on twitter/X: https://x.com/RickMatsen
Follow on facebook: https://www.facebook.com/shoulder.arthritis
Follow on LinkedIn: https://www.linkedin.com/in/rick-matsen-88b1a8133/


References

[1]Lewis PL, Gill DR, McAuliffe MJ, et al. Hip, Knee and Shoulder Arthroplasty: 2025 Annual Report. Australian Orthopaedic Association National Joint Replacement Registry. AOA: Adelaide; 2025. doi:10.25310/MXFR3061. (Figures ST1, ST2; Tables ST6, ST39, ST46–47, ST76.)

[2]Gupta MS, Krishan A, Rashid A, et al. Reverse versus anatomic total shoulder arthroplasty in patients over 70 with a competent rotator cuff and glenohumeral osteoarthritis: a meta-analysis. J Shoulder Elbow Surg. 2026 (online 2025). PMID: 41276069.

[3]Thamrongskulsiri N, Limskul D, Tanpowpong T, et al. Comparison of revision rates and clinical outcomes between anatomic and reverse total shoulder arthroplasty for rotator cuff-intact osteoarthritis: a systematic review and meta-analysis. Clin Orthop Surg. 2025;17(6):907–921. doi:10.4055/cios25012.

[4]Kim H, Kim CH, Kim M, et al. Is reverse total shoulder arthroplasty more advantageous than anatomic TSA for osteoarthritis with intact cuff tendon? A systematic review and meta-analysis. J Orthop Traumatol. 2022;23(1):3. PMID: 34993646.

[5]Kirsch JM, Puzzitiello RN, Swanson D, et al. Outcomes after anatomic and reverse shoulder arthroplasty for glenohumeral osteoarthritis: a propensity score-matched analysis. J Bone Joint Surg Am. 2022. PMID: 35867705.

[6]O’Malley O, Davies A, Sabharwal S, et al. Is there a difference in thresholds for revision between shoulder arthroplasty types? A National Joint Registry study. PLoS One. 2025. doi:10.1371/journal.pone.0330975.

[7]Werner BC, Lederman E, Gobezie R, et al. Understanding the variables associated with failure to achieve an acceptable symptom state after reverse shoulder arthroplasty. Semin Arthroplasty JSES. 2021.

[8]Ardebol J, et al. Defining the MCID and PASS following reverse shoulder arthroplasty for glenohumeral arthritis or cuff tear arthropathy at minimum 5-year follow-up. JSES Int. 2025.

[9]Marigi EM, Hao KA, Friedman RJ, et al. Exactech Equinoxe anatomic versus reverse total shoulder arthroplasty for primary osteoarthritis: case-controlled comparisons using the machine learning-derived Shoulder Arthroplasty Smart score. J Shoulder Elbow Surg. 2023. PMID: 39292145.

[10]Beleckas CM, Schodlbauer DF, Mousad AD, et al. Evaluation of new normal after shoulder arthroplasty: comparison of anatomic vs. reverse total shoulder arthroplasty. J Shoulder Elbow Surg. 2025;34:S43–S49. doi:10.1016/j.jse.2025.02.010. PMID: 40074195.

[11]Barco R, Savvidou OD, Sperling JW, et al. Complications in reverse shoulder arthroplasty. EFORT Open Rev. 2016;1:72–80. doi:10.1302/2058-5241.1.160003.

[12]Leinweber KA, Bowler AR, Diestel DR, et al. Reverse and anatomic total shoulder arthroplasty for glenohumeral osteoarthritis: a propensity-matched comparison at early and midterm follow-up. J Shoulder Elbow Surg. 2026. PMID: 41564999.

[13]Sharareh B, Whitson AJ, Matsen FA III, et al. Minimum 10-year follow-up of anatomic total shoulder arthroplasty and ream-and-run arthroplasty for primary glenohumeral osteoarthritis. J Shoulder Elbow Surg. 2024;33(6):1276–1284. PMID: 37777045.

[14]Matsen FA III, Whitson A, Jackins SE, et al. Ream and run and total shoulder: patient and shoulder characteristics in five hundred forty-four concurrent cases. Int Orthop. 2019;43(9):2105–2115. PMID: 31240359.

[15]Liu JN, Steinhaus ME, Garcia GH, et al. Return to sport after shoulder arthroplasty: a systematic review and meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2018;26(1):100–112. PMID: 28409200.

[16]Abdelshaheed J, Chatterji R, Levy J, et al. Return to weightlifting following anatomic and reverse shoulder arthroplasty. J Shoulder Elbow Surg. 2026;35:1660–1666. doi:10.1016/j.jse.2026.02.002.

[17]Ames A, Shah SS, Pettit R, et al. Against surgeons’ advice: the return to sport in high-demand weightlifters following anatomic total shoulder arthroplasty at average 3.6 years’ follow-up. J Shoulder Elbow Surg. 2023;32(4):e153–e159. doi:10.1016/j.jse.2022.09.027.

[18]Menendez ME, Garrigues GE, Jawa A. Clinical Faceoff: anatomic versus reverse total shoulder arthroplasty for primary glenohumeral osteoarthritis. Clin Orthop Relat Res. 2022;480(11):2095–2100.

[19]Daher M, Fares MY, Boufadel P, et al. Patient-specific instrumentation in primary total shoulder arthroplasty: a meta-analysis of clinical outcomes. Clin Shoulder Elb. 2025;28(2):129–136. doi:10.5397/cise.2024.01095.

[20]Patient-specific instrumentation in shoulder arthroplasty: high tech, low yield? [editorial]. Clin Shoulder Elb. 2025;28(2). doi:10.5397/cise.2025.00423.

[21]Gaj E, Pagnotta SM, Berlinberg EJ, et al. Intraoperative navigation system use increases accuracy of glenoid component inclination but not functional outcomes in reverse total shoulder arthroplasty. Arch Orthop Trauma Surg. 2024;144(1):91–102. doi:10.1007/s00402-023-05038-y.

[22]Page RS, Alder-Price AC, Rainbird S, et al. Reduced revision rates in total shoulder arthroplasty with crosslinked polyethylene: results from the Australian Orthopaedic Association National Joint Replacement Registry. Clin Orthop Relat Res. 2022;480(10):1940–1949. doi:10.1097/CORR.0000000000002293. PMID: 35901440.

[23]Khan AZ, Maxwell MJ, Parrott RM, et al. Effect of vitamin E–enhanced highly cross-linked polyethylene on wear rate and particle debris in anatomic total shoulder arthroplasty: a biomechanical comparison to ultrahigh-molecular-weight polyethylene. J Shoulder Elbow Surg. 2024. PMID: 38182025.

[24]Gowd AK, Liu JN, Cabarcas BC, et al. Single Assessment Numeric Evaluation and patient acceptable symptom state thresholds following shoulder arthroplasty. J Shoulder Elbow Surg. 2021. (PASS: ASES 81.9, SANE 75.5; n=207, mixed TSA/RSA.)

[25]DeVito P, Damodar D, Berglund DD, et al. Predicting outstanding results after reverse shoulder arthroplasty using percentage of maximal outcome improvement. J Shoulder Elbow Surg. 2019;28(6):1223–1231. PMID: 30910258. (SST threshold 61.3% MPI; n=198.)

[26]Shah SS, Gaal BT, Roche AM, et al. The modern reverse shoulder arthroplasty and an updated systematic review for each complication: part I. JSES Int. 2020;4(4):929–943. (Periprosthetic joint infection 2.4% for primary RSA.)

[27]Shah SS, Roche AM, Sullivan SW, et al. The modern reverse shoulder arthroplasty and an updated systematic review for each complication: part II. JSES Int. 2020;5(1):121–137. doi:10.1016/j.jseint.2020.07.018. PMID: 33554177. (Instability, humerus/glenoid fracture, acromial/scapular-spine fracture.)

[28]Zumstein MA, Pinedo M, Old J, et al. Problems, complications, reoperations, and revisions in reverse total shoulder arthroplasty: a systematic review. J Shoulder Elbow Surg. 2011;20(1):146–157.

[29]Lau SC, Large R. Acromial fracture after reverse total shoulder arthroplasty: a systematic review. Shoulder Elbow. 2020;12(6):375–389. doi:10.1177/1758573219876486. PMID: 33281942.


Saturday, July 24, 2021

Shoulder arthritis with an intact rotator cuff - anatomic or reverse total shoulder?

 Glenohumeral osteoarthritis with intact rotator cuff treated with reverse shoulder arthroplasty: a systematic review

These authors aimed to summarize the current literature for rotator cuff intact osteoarthritis treated with primary reverse shoulder arthroplasty (RSA) and to determine whether morphological changes in the glenoid led to inferior outcomes.


They reviewed 13 studies reporting a minimum of 1 year followup for RSA in a total of 460 cases with rotator cuff intact osteoarthritis.


 


Patient reported outcomes were significantly improved for the Constant score but not for VAS, ASES, or Simple Shoulder Test scores.

The overall mean rate of major complication was 3.8%. The mean complication rate was 4.7% among shoulders with “static posterior instability”, “severe posterior subluxation”, “posterior glenoid wear >20ยบ”, “significant posterior glenoid bone loss”, “biconcave glenoid”, “B2 glenoid”, and/or “B/C glenoid”.


Comment: The authors state that their study supports the use of reverse total shoulder in the treatment of intact rotator cuff osteoarthritis with reverse shoulder replacement. However the outcomes from this review do not seem to match those achieved with anatomic total shoulder arthroplasty, even for shoulders with glenoid deficiencies and retroversion. Compare the clinical improvement in the Simple Shoulder Test reported above to that in the two articles below. 


We conclude that at present evidence is lacking that reverse total shoulder is superior to anatomic total shoulder arthroplasty for patients with primary osteoarthritis and an intact rotator cuff.



Anatomic Total Shoulder Arthroplasty with All-Polyethylene Glenoid Component for Primary Osteoarthritis with Glenoid Deficiencies

This study evaluated the ability of shoulder arthroplasty using a standard glenoid component to improve patient self-assessed comfort and function and to correct preoperative humeral-head decentering on the face of the glenoid in patients with primary glenohumeral arthritis and type-B2 or B3 glenoids. The SST score improved from 3.2 ± 2.1 points preoperatively to 9.9 ± 2.4 points postoperatively (p < 0.001) at a mean time of 2.8 ± 1.2 years for type-B2 glenoids and from 3.0 ± 2.5 points preoperatively to 9.4 ± 2.1 points postoperatively (p < 0.001) at a mean time of 2.9 ± 1.5 years for type-B3 glenoids; these results were not inferior to those for shoulders with other glenoid types. The mean humeral-head decentering on the glenoid face was reduced for type-B2 glenoids from -14% ± 7% preoperatively to -1% ± 2% postoperatively (p < 0.001) and for type-B3 glenoids from -4% ± 6% preoperatively to -1% ± 3% postoperatively (p = 0.027). The rates of bone integration into the central peg for type-B2 glenoids (83%) and type-B3 glenoids (81%) were not inferior to those for other glenoid types


In a population of patients undergoing TSA in whom no specific efforts were made to change the version of the glenoid, the authors asked whether at 2 years after surgery patients having glenoid components implanted in 15° or greater retroversion had (1) less improvement in the Simple Shoulder Test (SST) score and lower SST scores; (2) higher percentages of central peg lucency, higher Lazarus radiolucency grades, higher mean percentages of posterior decentering, and more frequent central peg perforation; or (3) a greater percentage having revision for glenoid component failure compared with patients with glenoid components implanted in less than 15° retroversion.

The mean (± SD) improvement in the SST (6.7 ± 3.6; from 2.6 ± 2.6 to 9.3 ± 2.9) for the retroverted group was not inferior to that for the nonretroverted group (5.8 ± 3.6; from 3.7 ± 2.5 to 9.4 ± 3.0). The mean difference in improvement between the two groups was 0.9 (95% CI, - 2.5 to 0.7; p = 0.412). The percent of maximal possible improvement (%MPI) for the retroverted glenoids (70% ± 31%) was not inferior to that for the nonretroverted glenoids (67% ± 44%). The mean difference between the two groups was 3% (95% CI, - 18% to 12%; p = 0.857). The 2-year SST scores for the retroverted (9.3 ± 2.9) and the nonretroverted glenoid groups (9.4 ± 3.0) were similar (mean difference, 0.2; 95% CI, - 1.1 to 1.4; p = 0.697). No patient in either group reported symptoms of subluxation or dislocation. The radiographic results for the retroverted glenoid group were similar to those for the nonretroverted group with respect to central peg lucency (four of 21 [19%] versus six of 50 [12%]; p = 0.436; odds ratio, 1.7; 95% CI, 0.4-6.9), average Lazarus radiolucency scores (0.5 versus 0.7, Mann-Whitney U p value = 0.873; Wilcoxon rank sum test W = 512, p value = 0.836), and the mean percentage of posterior humeral head decentering (3.4% ± 5.5% versus 1.6% ± 6.0%; p = 0.223). The  percentage of patients with retroverted glenoids undergoing revision (0 of 21 [0%]) was not inferior to the percentage of those with nonretroverted glenoids (three of 50; [6%]; p = 0.251).

How you can support research in shoulder surgery Click on this link.

Here are some videos that are of shoulder interest
Shoulder arthritis - what you need to know (see this link).
How to x-ray the shoulder (see this link).
The total shoulder arthroplasty (see this link).
The ream and run technique is shown in this link.
The cuff tear arthropathy arthroplasty (see this link).
The reverse total shoulder arthroplasty (see this link).
Shoulder rehabilitation exercises (see this link).

Follow on twitter: Frederick Matsen (@shoulderarth)

Sunday, February 14, 2021

Glenohumeral arthritis with an intact rotator cuff: anatomic and reverse total shoulder

Value Analysis of Anatomic and Reverse Shoulder Arthroplasty for Glenohumeral Osteoarthritis with an Intact Rotator Cuff

These authors used the average and incremental cost-effectiveness ratio (ACER and ICER) and the procedure value index (PVI) to examine differences in outcomes and value between TSA and RSA for treatment of glenohumeral osteoarthritis with an intact rotator cuff. They performed a retrospective matched-cohort study of patients treated with primary shoulder arthroplasty for osteoarthritis with an intact rotator cuff who had a minimum 2-year follow-up. 


Patients treated with aTSA were matched 4:1 to those treated with RSA based on sex, age, and preoperative SST score. 


Two hundred and fifty-two aTSA-treated patients were matched to 63 RSA-treated patients with no significant differences in sex, age, or preoperative SST score. Total hospitalization costs, charges, and reimbursements along with outcome improvements in units of minimal clinically important differences (MCIDs) and patient satisfaction did not differ between the groups. For RSA, the implant cost was significantly higher than that for aTSA, but the operating room, anesthesia, and cement costs were lower. The aTSA group had a 3.2% rate of gross glenoid loosening and a 2.4% revision rate at an average followup of 54 (24-122) months. There was no loosening or revision in the RSA group at an average of 38 (24-85) months. 


None of the value analytics differed between groups even after inclusion of the outcomes and costs of early aTSA revisions. The patients having revision were 72, 80, 76, 77, 75, and 88 years of age at the time of revision and had an A2, B2, A1, A2, D, and B3 glenoid prior to the primary aTSA, respectively. The reasons for failure in these individual patients were (1) subscapularis tear, (2) massive rotator cuff tear, (3) massive rotator cuff tear, (4) subscapularis tear with gross loosening, (5) massive rotator cuff tear with gross loosening, and (6) infection with gross loosening. A second comparative value analysis including the outcomes and costs of these revisions resulted in no significant differences in any ACER or PVI between aTSA and RSA.


Comment: This is a well-done study showing that under ideal circumstances both aTSA and RSA can yield comparable value. The complication and reoperation rates in this study for both procedures were remarkably low.


The authors are thorough in their presentation of its limitations:


(1) These results are from a high volume shoulder arthroplasty surgeon at a high volume medical center.  They may not be generalizable to lower volume practices. 


In comparison to low surgeon volume, high surgeon volume can result in a number of factors that enter the value calculation

    (a) lower negotiated costs of implants (sometimes <25% of the "sticker price")

    (b) more refined patient selection (with consideration of patient health, motivation, social support and insurance status) resulting in fewer consultations and shorter hospital stays

    (c) better surgical technique with fewer complications

    (d) better operating room efficiency (lower operating room and anesthesia costs)

    (e) consistent and experienced anesthesia, nursing, and therapy resulting in decreased complication rates, shorter lengths of hospital stay, and lower hospitalization costs

  

(2) There was inherent selection bias in this retrospective cohort analysis, as there were a variety of justifications for selecting RSA  or aTSA. Patients were not randomized to RSA or aTSA and

decisions were based on surgeon and patient preference.


(3) The average followup duration was shorter for the RSA (38 months) patients than for the aTSA patients (54 months).


(4) The implants used for aTSA and RSA used are not presented.



Here are some videos that are of shoulder interest
Shoulder arthritis - what you need to know (see this link).
How to x-ray the shoulder (see this link).
The ream and run procedure (see this link).
The total shoulder arthroplasty (see this link).
The cuff tear arthropathy arthroplasty (see this link).
The reverse total shoulder arthroplasty (see this link).
The smooth and move procedure for irreparable rotator cuff tears (see this link).
Shoulder rehabilitation exercises (see this link).